anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a tumor apoptosis inducing ligand gene, gene expression protein and a preparation method thereof, which relates to the biotechnical field of medicines. The present invention clones Chinese Trail full-length cDNA. Compared with the reported Euramerian population sequences, the present invention discoveries that the number 598 basic group of an end 5' changes C into G to change the number 200 threonine of an end N, which is encoded by the number 598 basic group, into alanine. Thereby, the present invention proves that the cDNA sequence specifically belongs to the Chinese population. The present invention establishes a Trail efficient prokaryotic expression system by the Trail full-length cDNA. The cloned Trail full-length cDNA respectively clones soluble extracellular Trail109 cDNA and Trail114 cDNA and respectively establishes a trail109cDNA prokaryotic expression system and a trail114 cDNA prokaryotic expression system. The prokaryotic expression systems established by the present invention greatly improve the expression amount of tumor apoptosis inducting ligand protein in Trail, Trail109 and Trail114, and can provide a new preparation for killing tumor cells.
Background: Increasing evidence supporting the clinical effectiveness of cooled radiofrequency ablation (RFA) therapy for genicular nerves in patients with chronic knee osteoarthritis (OA) exists. However, no study has been conducted to eliminate the potential influence of a placebo effect associated with this procedure. Therefore, we evaluated the efficacy of cooled RFA compared with a sham procedure in patients with painful knees due to OA. Methods: In this double-blind, randomized, controlled study, participants were randomly assigned to receive cooled RFA of the knee (cooled RFA group, n = 20) or a sham procedure (sham group, n = 20). The primary outcome was the proportion of successful responders at the three-month follow-up. The secondary outcomes were successful responders at one and six months; pain intensity of the knee; functional status; medication; and satisfaction at one, three, and six months after the procedures. Results: For the primary outcome, the successful responder rate was significantly higher in the cooled RFA group (76.5%) than in the sham group (33.3%) (p = 0.018). For the secondary outcome, more successful responders were observed in the cooled RFA group than in the sham group at one and six months after the procedure (p = 0.041 and 0.007, respectively). The decreased knee pain intensity was maintained throughout the six-month follow-up period in the cooled RFA group. No differences were observed in functional status, medication change, or satisfaction in both groups. Conclusions: The cooled RFA of genicular nerves offers significant pain relief and surpasses the effects attributable to a placebo.
This study is to explore the optimization of anti-onychomycosis patch with various formulation contents (three patch groups: 3%, 6% and 8% of terbinafine (contains 3-mg, 6-mg and 8-mg/patch terbinafine, respectively) combined with fixed 2% ketoconazole (contains 2-mg ketoconazole/patch) and its safety profile. At least 18 patients (age: 20 to 75 years old) with one or two feet toenails infected simultaneously need to complete the whole study. Patients will be assigned to one of patch groups. The patients with only one infected toenail will also apply one patch on other foot with uninfected toenail. The patch will be applied on the foot on the dorsal site and leave it there for two consecutive days. Totally six patches will be used for each week. The duration of therapy will be 24 weeks. The patients' blood sample and toenail clippings will be collected every 8 weeks and will be analyzed as well as the safety profiles. The most appropriate patch formulation will be selected on the drug content residues in toenail. The safety profile will be also presented and discussed with various anti-onychomycosis patch formulations.
PROBLEM TO BE SOLVED: To obtain a skin-whitening cosmetic that shows excellent melanin- formation inhibitory action and has good skin whitening effect with high safety by using an extract of a specific plant. SOLUTION: This skin-whitening cosmetic contains an extract of a plant, Zingiber zerumbet Smith, or a chemical compound, zerumbone represented by the formula. This extract is obtained by extracting leaves, roots, stems, subterranean stems or the whole body of the plant with water or a solvent as methanol, ethanol, propanol or the like or their mixed solvent. The amount of the extract is 0.0001-10 wt.% of the whole cosmetic on the dry basis. The zerumbone is obtained by extracting the plant body of Zingiber zerumbet with ethanol or the like, distilling off the solvent and purifying the residue with the column chromatography. The content of the zerumbone in the cosmetic is 0.0000001-0.1 wt.%.
The knowledge of normal diameter of lumbar spinal canal is very important for diagnosing lumbar spinal canal stenosis and also for performing spinal surgeries at the lumbar level by Neurosurgeons and Orthopedicians. However, it varies widely among ethnic groups and between sexes in the same ethnic group . Spinal canal stenosis (defined as the narrowing of central spinal canal) is a condition in which the anteroposterior (AP) and lateral dimensions of the bony spinal canal are less than normal for corresponding age and sex. Back pain is the commonest manifestation of lumbar canal stenosis which usually results from lumbar spondylosis. Lumber lordosis is a problem of adults, but is now being increasingly seen in youth, probably due to lifestyle changes. Multiple factors play a role in spondylosis, but if it is associated with spinal canal stenosis, its management differs. Radiological evaluation forms an important part in the evaluation and management of lumbar spondylosis. But it requires clear understanding of the normal dimensions of lumbar vertebrae for particular age \& sex . Multislice computed tomography (MSCT) scans provides a noninvasive, non-operator dependent method of direct imaging of the spinal canal without injection of intra thecal contrast and is better than MRI for bony detail as in osteophytes. Though there is a wide variation in the capacity of spinal canal in patients who are clinically and radiologically normal. It is said that those with smaller canals are more likely to have symptoms from nerve root compression . By determining normal ranges of spinal canal diameter investigators can make early diagnosis in individuals who have lower diameters of spinal canal. These individuals are predisposed to spinal canal stenosis, which is a major cause of spinal radiculopathies. The recent use of CT for the measurements of the vertebral dimensions such as canal diameter and vertebral dimension has led to better evaluation of vertebral morphometry as compared with x-ray and cadaveric studies . CT scan measurement of lumbar spine demonstrated a mean AP canal diameter between 12 mm and 14 mm with a measurement of 11.5 mm considered small. On CT scan, electronic measurement of the sagittal diameter of the normal bony canal is 11.5 mm . These differences in dimension of the spinal canal across studies demands necessity of study of dimension of the spinal canal in every ethnic group.
Recruitment for this group will take place at either the radiation-oncology department or at the colorectal surgery department, at the time of consultation or at the time of diagnosis, before the treatment setting. Once clinical staging is available, the surgeon and/or radiation-oncologist and/or research assistant should identify eligible patients. Patients that comply with selection criteria (inclusion/exclusion) will be approached by a research team member. For those patients interested in participating, the e-link to the consent form for this group will be sent by email. Once a patient decides to sign the consent form, the link for the questionnaire Q1 will be sent by email.
Doped zinc oxide powder comprises doping component (0.005-15 wt.%). The doping component comprises oxides of aluminum, gallium, indium, germanium, tin, and/or silicon. The zinc oxide powder is in the form of aggregates having a mean maximum diameter of 30-300 nm.  An Independent claim is also included for preparation of zinc oxide powder by treating zinc powder and doping agent(s) in vaporization, nucleation, oxidation, and quenching zones. In the vaporization zone, zinc powder is vaporized in a flame of air and/or oxygen and combustion gas under reaction conditions that oxidation of zinc does not occur. The hot reaction mixture from the vaporization zone containing zinc vapor, water vapor (reaction product of flame reaction), and optionally excess combustion gas passes through the nucleation zone and is cooled to 500-900degreesC or is cooled using inert gas, and an aerosol containing doping agent(s) is fed in an amount that corresponds to the desired amount of doping agent in the zinc oxide powder. In the oxidation zone, the mixture from the nucleation zone is oxidized with air and/or oxygen. In the quenching zone, the oxidation mixture is cooled to less than 400degreesC by addition of cooling gas.
The study will be randomized clinical trial and will be conducted in Bahawalpur. The study will be completed in time duration of 6 months after approval of synopsis. Non probability convenience sampling technique will be used and 22 children will be recruited in the study meeting the inclusion criteria. The participants will be divided into two groups through randomization using lottery method. Group A will perform 10-15 minutes of stationary cycle training, 3 times a week for 6 weeks. While group B will be given progressive functional training 3 times a week for 10-15 minutes for 6 weeks. Pediatrics balance scale will be used to measure functional balance skills and GMFS scale will be used to measure gross motor function. The data will be assessed at the baseline and after 6 weeks of intervention. After data collection data will be analyzed by using SPSS version 25.
This study is a phase Ib, single-center, single-arm exploratory clinical study designed to evaluate the safety and efficacy of Golidocitinib in combination with PD-1 monoclonal antibody in locally advanced or metastatic NSCLC treated with PD-1 monoclonal antibody in combination with or without platinum-containing chemotherapy regimens. The purpose of this part is to obtain the safety profile of the Golidocitinib in combination with PD-1 monoclonal antibody regimen in subjects with NSCLC who have failed treatment with first-line PD-1 monoclonal antibody in combination with or without platinum-containing chemotherapeutic regimens, and the recommended dose of the combination. The study will enroll 30 patients receiving Golidocitinib administered once daily (orally) at a starting dose of 75 mg up to a maximum dose of 150 mg; PD-1 monoclonal antibody at a clinically standardized dose (e.g., 200 mg IV Q3W), until the patients experienced disease progression, intolerable toxicity, or met the criteria for discontinuation of the trial drug. The primary endpoint was ORR, and secondary endpoints included PFS, DCR, OS, and safety. The study is expected to commence recruitment in mainland China in about Dec 2024. It is expected that the trial will end in July 2027.
The protocol predefined aim of this study is to assess sustained effects of the OptiTrain trial on several health outcomes, 5 years after the baseline assessment. The OptiTrain study was a prospective, randomised controlled trial with 240 patients with breast cancer undergoing adjuvant chemotherapy that compared the effects of 16 weeks of two exercise programs, RT-HIIT and AT-HIIT, with usual care (UC). After a 5-year follow-up, eligible participants were evaluated for the primary outcome of cancer-related fatigue (CRF) and secondary outcomes including quality of life, symptoms, muscle strength, cardiorespiratory fitness, body mass, physical activity, and sedentary behavior. Statistical analysis was conducted using linear mixed models adjusted for baseline values. Tumour profile and menopausal status were additionally adjusted for CRF. Mean differences (MD), 95% confidence intervals (CIs), and standardized effect sizes (ES) were reported. At the 5-year follow-up, there were no statistically significant differences in total CRF between the intervention groups and the UC group. RT-HIIT reported significantly reduced pain sensitivity at the gluteus MD = 79.00 (95% CI 10.17, 147.83, ES = 0.55) compared to UC. Clinically meaningful differences for an increase in cognitive CRF and cardiorespiratory fitness were observed for the AT-HIIT versus UC group, and for lower limb strength for the RT-HIIT versus UC group, albeit without statistical significance. Engaging in targeted exercise during adjuvant chemotherapy for breast cancer provides short-term benefits in reducing fatigue and maintaining physical function. However, our 5-year follow-up indicates that these effects are limited in the long term. This underscores the need to support breast cancer survivors maintain their PA levels throughout their survivorship journey.
The intervention will be delivered in group-based education workshop format. The education session is a curriculum-based group education; each group will be having about 15-20 participants. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics.(a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion. This session is to increase knowledge, change cultural beliefs and attitudes on risks of CRC and benefits of screening by using interactive discussion approaches, visual aids, motivation video and print materials.
Cosmetic or pharmaceutical composition comprises a peptide or polypeptide fragment of solute carrier family 24, member 5(SLC24A5) protein or its biologically active derivative, comprising 4-50, preferably 4-8 amino acid residues, and of which sequence comprises a peptide sequence (I), in a medium. Cosmetic or pharmaceutical composition comprises a peptide or polypeptide fragment of solute carrier family 24, member 5(SLC24A5) protein or its biologically active derivative, comprising 4-50, preferably 4-8 amino acid residues, and of which sequence comprises a peptide sequence of formula ((AA) n-Thr-X1-X2-Ala-(AA) p) (I), in a medium. X1 : any aliphatic amino acid (Leu, Val, Ala or Ile); X2 : phenylalanine or any aliphatic amino acid; AA : any amino acid or one of its derivatives; and n and p : 0-4. An independent claim is included for a process for cosmetic treatment comprising applying the composition topically on the area to be treated. ACTIVITY : Dermatological. MECHANISM OF ACTION : None given. No biological data given.
The intervention, "LiveWell" will teach participants dialectical behavioral therapy-based skills to reduce psychological distress through improved physical symptom management, emotion regulation, and tolerance of uncertainty. Informed by feedback from patients and providers collected in Phase of of the study, the LiveWell intervention consists of of 8 sessions delivered one-on-one, approximately weekly. Sessions will last approximately 45-60 minutes each.
The intervention group will also receive Virtual coaching. The coach will evaluate goals, progress, facilitators (use of the buddy system) and barriers with an emphasis on forming healthy PA habits that will be sustained long-term over the life course. Social support: For the social support component, we will provide ground rules for communication (e.g., positive posts, use of "likes", comments, etc.). Groups will be comprised of 4-6 participants with consecutive recruitment.
We presented a 100-second video to study participants to reduce stigma towards depression (a girl presenter). The protagonist discussed his own depression and how getting help assist her.
Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive progesterone plus placebo for another 6 weeks.
BACKGROUND & AIMS: Type 2 innate lymphoid cells (ILC2s) and interleukin-13 (IL-13) promote the onset of spasmolytic polypeptide-expressing metaplasia (SPEM) cells. However, little is known about molecular effects of IL-13 in SPEM cells. We now sought to establish a reliable organoid model, Meta1 gastroids, to model SPEM cells in vitro. We evaluated cellular and molecular effects of ILC2s and IL-13 on maturation and proliferation of SPEM cells.
METHODS: We performed single-cell RNA sequencing to characterize Meta1 gastroids, which were derived from stomachs of Mist1-Kras transgenic mice that displayed pyloric metaplasia. Cell sorting was used to isolate activated ILC2s from stomachs of IL-13-tdTomato reporter mice treated with L635. Three-dimensional co-culture was used to determine the effects of ILC2s on Meta1 gastroids. Mouse normal or metaplastic (Meta1) and human metaplastic gastroids were cultured with IL-13 to evaluate cell responses. Air-Liquid Interface culture was performed to test long-term culture effects of IL-13. In silico analysis determined possible STAT6-binding sites in gene promoter regions. STAT6 inhibition was performed to corroborate STAT6 role in SPEM cells maturation.
RESULTS: Meta1 gastroids showed the characteristics of SPEM cell lineages in vitro even after several passages. We demonstrated that co-culture with ILC2s or IL-13 treatment can induce phosphorylation of STAT6 in Meta1 and normal gastroids and promote the maturation and proliferation of SPEM cell lineages. IL-13 up-regulated expression of mucin-related proteins in human metaplastic gastroids. Inhibition of STAT6 blocked SPEM-related gene expression in Meta1 gastroids and maturation of SPEM in both normal and Meta1 gastroids.
CONCLUSIONS: IL-13 promotes the maturation and proliferation of SPEM cells consistent with gastric mucosal regeneration.
A method for the treatment of adrenoleukodystrophy or adrenomyeloneuropathy, in which there is administered to a human patient in need of the same an effective amount of hematopoietic cells modified ex vivo by infection with a retroviral vector containing a nucleic acid fragment comprising a sequence as represented on FIG. 2 (SEQ. ID No: 1) or FIG. 6 (SEQ. ID. No: 4-17) or FIG. 7 (SEQ. ID No: 18-23). Also, human hematopoietic cells can be treated ex vivo to correct the content of very long chain fatty acids in them, by providing human hematopoietic cells of a patient affected by adrenoleukodystrophy or adrenomyeloneuropathy, and infecting them ex vivo with a retroviral vector containing, operably linked to a promoter, a nucleic acid fragment as above. The expression of the nucleic acid in the hematopoietic cells corrects the content of very long chain fatty acids in the hematopoietic cells.
Dual blockade of the RAS with angiotensin-receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

The ONTARGET trial enrolled 25,620 patients ≥55 years old with atherosclerotic disease or diabetes with end-organ damage, randomizing them to telmisartan only, ramipril only, or the combination, and followed them for a median of 56 months. Patients receiving the combination of MICARDIS and ramipril did not obtain any additional benefit compared to monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute renal failure) compared with groups receiving telmisartan alone or ramipril alone.

In most patients no benefit has been associated with using two RAS inhibitors concomitantly. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function, and electrolytes in patients on MICARDIS and other agents that affect the RAS.

Do not co-administer aliskiren with MICARDIS in patients with diabetes. Avoid concomitant use of aliskiren with MICARDIS in patients with renal impairment (GFR <60 mL/min/1.73 m2).
Regulatory T cells (Tregs) residing in visceral adipose tissue (VAT) play a pivotal role in regulating tissue inflammation and metabolic dysfunction associated with obesity. However, the specific phenotypic and functional characteristics of Tregs in obese VAT, as well as the regulatory mechanisms shaping them, remain elusive. This study demonstrates that obesity selectively reduces Tregs in VAT, characterized by restrained proliferation, heightened PD-1 expression, and diminished ST2 expression. Additionally, obese VAT displays distinctive maturation of dendritic cells (DCs), marked by elevated expressions of MHC-II, CD86, and PD-L1, which are inversely correlated with VAT Tregs. In an in vitro co-culture experiment, only obese VAT DCs, not macrophages or DCs from subcutaneous adipose tissue (SAT) and spleen, result in decreased Treg differentiation and proliferation. Furthermore, Tregs differentiated by obese VAT DCs exhibit distinct characteristics resembling those of Tregs in obese VAT, such as reduced ST2 and IL-10 expression. Mechanistically, obesity lowers IL-33 production in VAT DCs, contributing to the diminished Treg differentiation. These findings collectively underscore the critical role of VAT DCs in modulating Treg generation and shaping Treg phenotype and function during obesity, potentially contributing to the regulation of VAT Treg populations.
Flavored dosage forms, e.g., lozenges and gums, are provided for sustained release of a flavoring agent in the mouth. The dosage forms provide sustained release by virtue of a wet matrix formed by admixture of a biocompatible, hydrophilic, water-insoluble polymer such as ethylcellulose and a flavoring agent, particularly an essential oil or a constituent thereof, e.g., a terpene or sesquiterpene. The dosage forms may also include a second beneficial agent in addition to the flavoring agent. Exemplary such beneficial agents include ionizable zinc compounds and other cold remedies, local anesthetic and anti-infective agents, diet aids, fluoride-releasing compounds, and nicotine. The dosage forms, when formulated as lozenges, may be somewhat adhesive or substantially nontacky, depending primarily on the molecular weight of the hydrophilic polymer. Adhesive lozenges can serve as dosage forms that adhere to the teeth or gums for delivery of a beneficial agent thereto. Methods for using the dosage forms to provide sustained release of a flavoring agent and optionally deliver a second beneficial agent are also provided, as are methods for treating the common cold, treating a sore throat, facilitating weight loss, and assisting in smoking cessation.
Recent research has linked systemic metabolic disorders to cognitive decline and dementia risk, including Alzheimer's. This is suspected to be due to lifestyle-related vascular impairments from atherosclerosis and other factors, such as malnutrition and anaemia. Applying deep learning using 2897 cases from a rehabilitation hospital and health screenings, we trained a model to predict cognitive function [mini-mental state examination (MMSE) scores] and brain atrophy [Brain Healthcare Quotient (BHQ) scores] from basic blood tests and age. The deep learning model accurately estimated MMSE and BHQ from these inputs, with age, nutritional information, and organ function indicators being top predictors. These findings highlight the relationship of dementia with systemic metabolic disorders and suggest the potential of using routine blood tests for dementia risk assessment. Furthermore, personalised dietary interventions could be tailored based on blood test anomalies. This holistic view mirrors traditional Chinese medicine, which considers brain disorders systemic, that is related to vital organs but not the brain itself.